Cellectis S.A. (CLLS) Stock

About Cellectis S.A.

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.

Cellectis S.A. is headquartered in FR.

Cellectis S.A. (CLLS) stock trades at $2.81 with a market capitalization of $282.17M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.14, reflecting a net loss over the last twelve months, price-to-book of 4.69, price-to-sales of 2.97. Over the past 52 weeks the stock has ranged between $1.77 and $5.48, and currently trades 48.7% below its 52-week high.

On profitability, Cellectis S.A. generates a return on equity (ROE) of -80.61% (negative, reflecting a net loss), return on capital employed of -30.50%, an operating margin of -69.23%, a net profit margin of -98.69%.

Official website: www.cellectis.com

Cellectis S.A. by the numbers, 2016–2025

Between 2016 and 2025 Cellectis S.A. reported revenue of $43.0M rising to $73.0M, a change of +69.8% across 10 years. Compounded, revenue has grown 7.4% a year over five years, 56.6% over three, 73.8% over the last twelve months. Net profit fell to $-68.0M.

Operating margin went from -150.2% in 2016 to -45.3% in 2025, a gain of 104.9 percentage points. The most recent net margin is -98.69%. On a trailing twelve-month basis to Mar '26, revenue is $68.0M and net profit $-67.0M.

Borrowings rose from $2.0M to $120.0M, cash on hand is $185.7M, cash from operations was $-40.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -75.6% over five years, and was -89.5% in the most recent year.

The share price itself has compounded at -27.6% a year over five years, 7.8% over three, 33.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cellectis S.A. (CLLS) — frequently asked questions